Disease · HP_0200026
Ocular pain
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Ocular pain. Diseases, record HP_0200026. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0200026
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Ocular pain
- Open Targets ID
- HP_0200026
- Other names
- Eye pain
- Highest stage of its drugs
- Approval, for 3 of its 13 drugs, from DailyMed and TTD
Source Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| KETOROLAC TROMETHAMINE | CHEMBL1201124 | Small molecule | Approval | DailyMed | 4 | 1 | 1 | Drugs and targets |
| DIFLUPREDNATE | CHEMBL1201749 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| BROMFENAC SODIUM | CHEMBL3181947 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| NEPAFENAC | CHEMBL1021 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BROMFENAC | CHEMBL1077 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LOTEPREDNOL ETABONATE | CHEMBL1200865 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMAVELOXOLONE | CHEMBL4303525 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SAF312 | CHEMBL3544953 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TIVANISIRAN | CHEMBL3707356 | Oligonucleotide | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 4 | Cyclooxygenase inhibitor | Approval | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 4 | Cyclooxygenase inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| TRPV1 | TRPV1 mRNA | 2 | Vanilloid receptor inhibitor; Vanilloid receptor mRNA antisense inhibitor | Phase 2 | https://conductscience.org/library/genes/7442 | Drugs and targets |
| DRD2 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Unknown | https://conductscience.org/library/genes/1813 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Unknown | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Unknown | https://conductscience.org/library/genes/1815 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 1 | Serotonin 2a (5-HT2a) receptor antagonist | Unknown | https://conductscience.org/library/genes/3356 | Drugs and targets |
| NFE2L2 | Nuclear factor erythroid 2-related factor 2 | 1 | Nuclear factor erythroid 2-related factor 2 activator | Phase 2 | https://conductscience.org/library/genes/4780 | Drugs and targets |
Trials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01109173 | Confirmatory Study Nepafenac 0.3% | Phase 3 | 2,120 | 2012-11-30 | Cataract | NEPAFENAC | Its record names the disease | ClinicalTrials.gov |
| NCT01318499 | Nepafenac 0.3% Two Study | Phase 2 | 1,342 | 2012-12-17 | Cataract | NEPAFENAC | Its record names the disease | ClinicalTrials.gov |
| NCT02208297 | Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Phase 3 | 326 | 2020-09-03 | Inflammation, Pain, Cataract | LOTEPREDNOL ETABONATE | Its record names the disease | ClinicalTrials.gov |
| NCT00853970 | Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery | Phase 3 | 299 | 2011-01-26 | Pain, Inflammation | BROMFENAC | Its record names the disease | ClinicalTrials.gov |
| NCT00429923 | Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a) | Phase 3 | 219 | 2009-07-02 | Inflammation | DIFLUPREDNATE | Its record names the disease | ClinicalTrials.gov |
| NCT00704418 | Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery | Phase 3 | 156 | 2011-01-26 | Cataract | BROMFENAC | Its record names the disease | ClinicalTrials.gov |
| NCT02065375 | RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery | Phase 2 | 109 | 2023-04-19 | Inflammation and Pain Following Ocular Surgery | OMAVELOXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT03496467 | Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract | Phase 2 | 56 | 2021-10-12 | Pain, Inflammation | NEPAFENAC | Its record names the disease | ClinicalTrials.gov |
| NCT02961062 | Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery | Phase 2 | 40 | 2019-04-11 | Postoperative Ocular Pain After PRK Surgery | SAF312 | Its record names the disease | ClinicalTrials.gov |
| NCT00405730 | Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo | Phase 3 | 227 | Cataracts | KETOROLAC TROMETHAMINE, NEPAFENAC | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Loteprednol Etabonate Gel (BID) vs Vehicle Gel (BID): Percentage of Participants With Grade 0 Pain in the Study Eye. | 120 of 163 | 97 of 163 | 326 | NCT02208297 | Trial comparisons |
| Loteprednol Etabonate Gel (BID) vs Vehicle Gel (BID): Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells | 38 of 163 | 29 of 163 | 326 | NCT02208297 | Trial comparisons |
| Loteprednol Etabonate Gel (BID) vs Vehicle Gel (BID): deaths from any cause | 0 of 162 | 0 of 163 | 325 | NCT02208297 | Trial comparisons |
| Loteprednol Etabonate Gel (BID) vs Vehicle Gel (BID): serious adverse events | 0 of 162 | 1 of 163 | 325 | NCT02208297 | Trial comparisons |
| Bromfenac Ophthalmic Solution 0.09% vs Placebo: Summed Ocular Inflammation Score (SOIS) of Zero | 70 of 152 | 36 of 147 | 299 | NCT00853970 | Trial comparisons |
| Bromfenac Ophthalmic Solution 0.09% vs Placebo: Pain Free | 135 of 152 | 105 of 147 | 299 | NCT00853970 | Trial comparisons |
| Bromfenac Ophthalmic Solution 0.09% vs Placebo: serious adverse events | 0 of 147 | 3 of 144 | 291 | NCT00853970 | Trial comparisons |
| Bromfenac vs Placebo: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero | 36 of 78 | 23 of 78 | 156 | NCT00704418 | Trial comparisons |
| Bromfenac vs Placebo: Number of Participants That Are Pain Free | 65 of 78 | 40 of 77 | 155 | NCT00704418 | Trial comparisons |
| Bromfenac vs Placebo: serious adverse events | 0 of 73 | 0 of 73 | 146 | NCT00704418 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0200026
GET https://conductscience.org/api/diseases/v1/HP_0200026/drugs